Amo Pharma has reported positive results from its Phase II trial evaluating the safety and efficacy of AMO-02 (tideglusib), a GSK3β inhibitor, for the treatment of patients with autism spectrum disorder (ASD). In the randomised, double-blinded study, 83 adolescents with ASD received AMO-02 or placebo over 12 weeks. The drug was found to be generally safe and well tolerated. Patients receiving AMO-02 recorded improvements over placebo in measures of social withdrawal (ABC-Social) and repetitive behaviours (RBS-R), as well as daily living skills (Vineland), memory (NEPSY) and sleep quality (CSHQ).
Chief Medical Officer, Joe Horrigan, said that treatment with AMO-02 has the potential to offer meaningful, multi-symptom benefit in ASD.
Amo Pharma is also advancing development of AMO-04, a glutamate modulator, for the treatment of Rett syndrome, for which it has entered into a development and licensing agreement with Numedicus Limited
https://globalgenes.org/raredaily/a...-study-of-amo-02-in-autism-spectrum-disorder/
https://www.drugdevelopment-technology.com/news/amo-pharma-reports-positive-results-from-tide-trial/
https://www.amo-pharma.com/index.htm
Amo Pharma has reported positive results from its Phase II trial...
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.60 |
Change
0.000(0.00%) |
Mkt cap ! $1.993B | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9814 | $17.29 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.50 | 1650 | 2 |
View Market Depth
| Last trade - 09.46am 15/08/2024 (20 minute delay) ? |
| NEU (ASX) Chart |
Day chart unavailable